Get started
Work

Wcn24-756 Povetacicept, an Enhanced Dual Baff/april Antagonist, in Autoantibody-associated Glomerulonephritis

Year: 2024
Type: article
Abstract: The cytokines BAFF and APRIL are clinically validated targets in multiple autoantibody-associated diseases. Their inhibition has shown promise in IgA nephropathy (IgAN), lupus nephritis (LN), and primary membranous nephropathy (pMN), with the potential to exert a disease-modifying effect. Povetacicept (ALPN-303) is an Fc fusion protein of a variant TACI domain engineered for more potent dual BAFF/APRIL inhibition than wild-type TACI or anti-BAFF or anti-APRIL antibodies. In healthy volunteers, povetacicept has been associated with on-target reductions in levels of immunoglobulin, including galactose-deficient IgA1 (Gd-IgA1), and antibody-secreting cells.
DOI: 10.1016/j.ekir.2024.02.291
Authors: James Tumlin, Sreedhar Mandayam, Arvind Madan, Frank Cortazar, Sang-Woong Han, Hemant Kulkarni, Jonathan Barratt, Brad Rovin, Hong Zhang, Rupert Davies, Amanda Enstrom, Heather Thomas, Jiahua Li, Stanford L. Peng, Harmeet Singh
Institutions: Emory University, The University of Texas MD Anderson Cancer Center, Hanyang University Guri Hospital, Royal Perth Hospital, East Metropolitan Health Service, University of Leicester, The Ohio State University, Peking University First Hospital, Alpine Immune Sciences (United States)
Language: English
Subfield: Nephrology
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,800
OpenAlex ID: W4393856267
FWCI:
Cites:
Cited by:
Related to: 10